Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;83(5):607-635.
doi: 10.1016/j.jinf.2021.08.017. Epub 2021 Aug 14.

Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19

Emmanuel Q Wey  1 , Clare Bristow  2 , Aarti Nandani  3 , Bryan O'Farrell  3 , Jay Pang  3 , Marisa Lanzman  3 , Shuang Yang  4 , Soo Ho  2 , Damien Mack  2 , Michael Spiro  5 , Indran Balakrishnan  2 , Sanjay Bhagani  2 , Gabriele Pollara  6
Affiliations
Comment

Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19

Emmanuel Q Wey et al. J Infect. 2021 Nov.
No abstract available

Keywords: Blood stream infection; C-reactive protein; COVID-19; CRP; Interleukin 6; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest We declare that all authors have no conflicts of interest

Figures

Fig. 1
Fig. 1
Inflammatory marker responses following tocilizumab administration and onset of BSI in COVID-19. (A) CRP concentration (left panel) and white cell count (right panel) relative to time since tocilizumab administration. All COVID-19 patients receiving tocilizumab included in analysis, independent of a subsequent presence of BSI (n = 107). (B) CRP concentration over time in patients that received tocilizumab and subsequently developed a BSI (n = 17). (C) CRP concentration of time in COVID-19 patients that developed a BSI but with no prior tocilizumab exposure (n = 55). (D) Change (Δ) in CRP induced by onset of BSI in COVID-19 patients stratified by prior receipt of tocilizumab. (E) Relationship between ΔCRP induced by BSI and time between administration of tocilizumab and the onset of BSI. Violin plots represent frequency distribution of all samples, with bold and dashed lines representing median and quartile values. All p values were calculated by Mann-Whitney tests.
See this image and copyright information in PMC

Comment on

References

    1. Rossotti R., Travi G., Ughi N., et al. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect. 2020;81(4):e11–e17. doi: 10.1016/j.jinf.2020.07.008. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: 10.1016/S0140-6736(21)00676-0. - DOI - PMC - PubMed
    1. Langford B.J., So M., Raybardhan S., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629. doi: 10.1016/j.cmi.2020.07.016. - DOI - PMC - PubMed
    1. Russell C.D., Fairfield C.J., Drake T.M., et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. June 2021 doi: 10.1016/S2666-5247(21)00090-2. - DOI - PMC - PubMed
    1. Mason C.Y., Kanitkar T., Richardson C.J., et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. January 2021 doi: 10.1093/jac/dkaa563. - DOI - PMC - PubMed